Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel in Patients With Coronary Atherosclerotic Heart Disease and Planned Percutaneous Coronary Intervention: a Multi-center, Randomized, Double-blind, Triple-dummy , Parallel-controlled, Dose-exploration Phase II Trial

NCT03599284 is registered in ClinicalTrials.gov with Jiangsu vcare pharmaceutical technology co., LTD as lead sponsor.

NCT NCT03599284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03599284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel in Patients With Coronary Atherosclerotic Heart Disease and Planned Percutaneous Coronary Intervention: a Multi-center, Randomized, Double-blind, Triple-dummy , Parallel-controlled, Dose-exploration Phase II Trial
Lead sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Phase
Phase 2
Overall status
Completed
Start date
August 30, 2018
Completion date
July 28, 2019
Enrollment
279 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, percutaneous coronary intervention, platelet aggregation inhibitors